OSR Health (OSRHW) Gains from Investment Securities (2024 - 2025)
OSR Health (OSRHW) posted Gains from Investment Securities of $19145.0 for Q4 2025, down 50.84% sequentially from $38941.0 in Q3 2025, and down 83.31% YoY from $114691.0 in Q4 2024.
OSR Health (OSRHW) Gains from Investment Securities (2024 - 2025) Analysis & Trends
OSR Health has reported Gains from Investment Securities for 2 years, with the latest figure at $19145.0 in Q4 2025.
- Quarterly Gains from Investment Securities fell 83.31% year-over-year to $19145.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158641.0 (changed N/A YoY) and the FY2025 annual result came in at $74079.0, down 56.17% from the prior year.
- Gains from Investment Securities fell to $19145.0 in Q4 2025 per OSRHW's latest filing, from $38941.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $114691.0 in Q4 2024 and troughed at -$14136.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19,145.00 |
| Dec 31, 2025 | 19,145.00 |
| Sep 30, 2025 | 38,941.00 |
| Sep 30, 2025 | 38,941.00 |
| Dec 31, 2024 | 114,691.00 |
| Dec 31, 2024 | 114,691.00 |
| Sep 30, 2024 | -14,136.00 |
| Sep 30, 2024 | -14,136.00 |